EZH2 and neoplasm: The pharmacokinetics of VX-689, MI-2, OTX-015, EZH2 inhibitors, and PTC-596 in the brain remain unknown, while studies on a multi-kinase drug (BMS-754807) demonstrated efficacy against H3.3-K27M murine cells in vitro but failed to reach IC50 levels in tumor tissue when dosed at 50 mg/kg in vivo [58] (Table 2).